Announcement

New Products Launched!

Auralief Oral Strips BLOOM Arousal Gel    

Newsroom

Insights into LOVE

Welcome to our newsroom where we post news, events, and financial updates.

June 2, 2023

JOLT HEALTH INC. ANNOUNCES NEW CEO AND DIRECTOR TO LEAD BIOTECHNOLOGY, HEALTHCARE AND AI INITIATIVES

VANCOUVER, BC, CANADA (June 2nd,  2023) – Jolt Health Inc. (“JOLT” and or “The Company”)(CSE: JOLT) (FSE: G1Q0) (previously Love

Read More

May 25, 2023

JOLT Health Inc. Announces Issuance of Common Shares in Satisfaction of Interest Payments to Promissory Note Holders and Interest Payment to Convertible Debenture Holder

VANCOUVER, BC, CANADA (May 25, 2023) – Jolt Health Inc. (formerly Love Pharma Inc.) (“Jolt” and or “the Company”) (CSE:JOLT)

Read More

May 16, 2023

LOVE PHARMA INC. ANNOUNCES CHANGE OF NAME TO “JOLT HEALTH INC.” AND INCREASED FOCUS ON BIOTECHNOLOGY

VANCOUVER, BC, CANADA (May 16, 2023) – LOVE Pharma Inc. (“LOVE” and or “the Company”) (CSE:LUV) (FSE: G1Q0)  is pleased

Read More

April 5, 2023

LOVE PHARMA TO EVALUATE MINING OPPORTUNITIES

VANCOUVER, BC, CANADA (April 5, 2023) – LOVE Pharma Inc. (“LOVE” and or “the Company”) (CSE:LUV) (FSE: G1Q0) is currently

Read More

April 3, 2023

LOVE PHARM INC. ANNOUNCES GRANT OF STOCK OPTIONS

VANCOUVER, BC, CANADA (April 3, 2023) – LOVE Pharma Inc. (“LOVE” and or “the Company”) (CSE:LUV) (FSE: G1Q0)  is pleased

Read More

February 27, 2023

LOVE PHARMA INC. ANNOUNCES SHARE CONSOLIDATION

VANCOUVER, BC, CANADA (February 27, 2023) – LOVE Pharma Inc. (“LOVE” and or “the Company”) (CSE:LUV) (FSE: G1Q0)  announced it

Read More

December 14, 2022

LOVE PHARMA SELLS MICRODOZ, INCREASES FOCUS ON BIOTECHNOLOGY

VANCOUVER, BC, CANADA (December 14th,  2022) – LOVE Pharma Co. (“LOVE” and or “The Company”)(CSE: LUV) (FSE: G1Q0), the Company

Read More

November 2, 2022

LOVE PHARMA INVESTEE, STARTON THERAPEUTICS, STRENGTHENS BOARD WITH NEW MEMBER (RE-RELEASE)

Please see the previously announced news from Starton Therapeutics Inc. VANCOUVER, BC, CANADA (November 2nd,  2022) – LOVE Pharma Co.

Read More

October 20, 2022

NALTREXONE DEMONSTRATES PROMISING LONG COVID APPLICATION

Naltrexone primarily used to treat alcohol and or opioid has now shown promise in treating Long COVID at low doses1

Read More

October 19, 2022

Love Pharma Closes Acquisition of Doc Hygiene

VANCOUVER, BC, CANADA (October 19th, 2022) – LOVE Pharma Co. (“LOVE” or the “Company”)(CSE: LUV) (FSE: G1Q0), is pleased to

Read More
1 2 3